Preliminary research has indicated that PD-1 inhibitors are effective in treating hematologic malignancies, such as classical Hodgkin’s lymphoma and follicular lymphoma, and may also be useful in DLBCL (14). The gene discussed is PDCD1; the disease is diffuse large B-cell lymphoma.